Intel Chain

# HEALTH INTEL: The Antibiotic Resistance Crisis and Historical Parallels Since Fleming's discovery of penicillin in 1928, antibiotics have prevented an estimated 200+ million deaths globally, yet resistance patterns now mirror the pre-antibiotic era mortality rates in certain pathogens—MRSA mortality rates have risen 40% since 2000. The CDC reports 2.8 million antibiotic-resistant infections annually in the US alone, with treatment failures pushing patients toward older, more toxic drug regimens last used in the 1950s. This matters because we're experiencing the reversal of a century of medical progress: routine surgeries, childbirth, and minor infections are becoming high-risk again, while the pharmaceutical pipeline has only approved 2 new antibiotic classes since 2010 versus dozens in mid-20th century. The economic burden reaches $35 billion annually in excess healthcare costs, disproportionately affecting developing nations where surveillance systems lack the infrastructure to track resistance emergence.